REVENUE MEMORANDUM CIRCULAR NO. 127-2021 issued on December 24, 2021 publishes the full text of the letter from Director General Rolando Enrique D. Domingo of the Food and Drug Administration with the subject “Response to Query on the List of VATExempt Products”.
             In the letter, FDA Director General Domingo clarified that ‘Liraglutide 6mg/mL Solution for Injection (SC)’ is only considered to be VAT-exempt if its use falls under the management of diabetes. Moreover, ‘Liraglitude 6mg/mL Solution for Injection (SC)’ under the brand name ‘Saxenda’, i.e. management of overweight and obesity, does not fall under the identified diseases included in both the TRAIN Law and the CREATE Act.